Biom Completes safety and efficacy data of BIO017 in preclinical Angelman Syndrome mouse model. Biom Therapeutics’ Open label clinical study show preliminary efficacy data of BIO017 in epileptic patients
Biom Therapeutics files for orphan disease designation for lead candidate BIO017. Biom Therapeutics meeting with FDA for pre-IND meeting
Biom Therapeutics partnered with Canopy Growth. Biom Therapeutics partnered with Alchem for clinical drug manufacturing for pivotal study
Biom Therapeutics invited for Biopitch in Annual BioFlorida Annual Event. Biom Therapeutics in final three companies presenting in BioPitch in Annual BioFlorida Annual Event
Dr. Thomas Patton joins the Biom Therapeutics as Chief Medical Officer
Biom ODD Filing
Biom Therapeutics filed Orphan Drug Designation for BIO017 with the FDA Published: December 17, 2020 SARASOTA, FL--(December 17, 2020) - Biom Therapeutics announces today that it has applied ...
Positive results from Lead drug candidate
Biom Therapeutics, LLC announces positive results from Phase 2 clinical trial for rare epilepsy disease Biom Therapeutics announces positive Phase 2 topline data results for their lead drug ...
Biom Therapeutics selected as a finalist at BioFlorida annual Biopitch competition for early-stage life science companies Biom Therapeutics receives prestigious recognition at BioFlorida annual conference. SARASOTA, Fl. Nov. ...